Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Emory University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Fondazione IRCCS Policlinico San Matteo di Pavia
M.D. Anderson Cancer Center
University of Miami
Regeneron Pharmaceuticals
Eastern Cooperative Oncology Group
IRCCS San Raffaele
University of Utah
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
European Myeloma Network B.V.
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Indiana University
Tufts Medical Center
Oslo University Hospital
University College, London
Dana-Farber Cancer Institute